HRP20120657T1 - Farmaceutski pripravak 271 - Google Patents

Farmaceutski pripravak 271 Download PDF

Info

Publication number: HRP20120657T1
Authority: HR; Croatia
Prior art keywords: pharmaceutical preparation; preparation according; benzoimidazole; phenylamino; bromo
Prior art date: 2008-03-28

Application number

HRP20120657AT

Other languages

English (en)

Croatian (hr)

Inventor

Frances Bateman Nicola

Richard Gellert Paul

Jane Hill Kathryn

Original Assignee

Astrazeneca Ab

Array Biopharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-28

Filing date

2012-08-13

Publication date

2012-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40792932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120657(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-08-13 Application filed by Astrazeneca Ab, Array Biopharma filed Critical Astrazeneca Ab

2012-09-30 Publication of HRP20120657T1 publication Critical patent/HRP20120657T1/hr

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract 6
239000011159 matrix material Substances 0.000 claims abstract 15
229940113116 polyethylene glycol 1000 Drugs 0.000 claims abstract 7
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims abstract 7
WWWTWPXKLJTKPM-UHFFFAOYSA-N 2-aminooxyethanol Chemical compound NOCCO WWWTWPXKLJTKPM-UHFFFAOYSA-N 0.000 claims abstract 6
125000005456 glyceride group Chemical group 0.000 claims abstract 6
XAAPQRFIXGDKPZ-UHFFFAOYSA-N 6-(4-bromo-2-chloroanilino)-7-fluoro-3-methylbenzimidazole-5-carboxylic acid Chemical compound OC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl XAAPQRFIXGDKPZ-UHFFFAOYSA-N 0.000 claims abstract 5
239000003937 drug carrier Substances 0.000 claims abstract 2
239000000825 pharmaceutical preparation Substances 0.000 claims 21
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 14
238000002360 preparation method Methods 0.000 claims 11
239000007787 solid Substances 0.000 claims 10
KWYWKYLYEIQRMF-UHFFFAOYSA-N CN1C(C=C(C(O)=O)C(NC(C=CC(Br)=C2)=C2Cl)=C2F)=C2N=C1.NOCCO Chemical compound CN1C(C=C(C(O)=O)C(NC(C=CC(Br)=C2)=C2Cl)=C2F)=C2N=C1.NOCCO KWYWKYLYEIQRMF-UHFFFAOYSA-N 0.000 claims 9
AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims 6
239000003814 drug Substances 0.000 claims 6
239000002775 capsule Substances 0.000 claims 3
125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
239000000203 mixture Substances 0.000 claims 3
206010028980 Neoplasm Diseases 0.000 claims 2
208000024770 Thyroid neoplasm Diseases 0.000 claims 2
201000011510 cancer Diseases 0.000 claims 2
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 2
229940079593 drug Drugs 0.000 claims 2
201000001441 melanoma Diseases 0.000 claims 2
238000002156 mixing Methods 0.000 claims 2
229920001223 polyethylene glycol Polymers 0.000 claims 2
201000002510 thyroid cancer Diseases 0.000 claims 2
208000003174 Brain Neoplasms Diseases 0.000 claims 1
206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
229940100198 alkylating agent Drugs 0.000 claims 1
239000002168 alkylating agent Substances 0.000 claims 1
210000000481 breast Anatomy 0.000 claims 1
210000004027 cell Anatomy 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
210000001072 colon Anatomy 0.000 claims 1
210000003238 esophagus Anatomy 0.000 claims 1
210000003128 head Anatomy 0.000 claims 1
239000008240 homogeneous mixture Substances 0.000 claims 1
210000003734 kidney Anatomy 0.000 claims 1
239000007788 liquid Substances 0.000 claims 1
210000004072 lung Anatomy 0.000 claims 1
201000005202 lung cancer Diseases 0.000 claims 1
208000020816 lung neoplasm Diseases 0.000 claims 1
238000002844 melting Methods 0.000 claims 1
230000008018 melting Effects 0.000 claims 1
238000000034 method Methods 0.000 claims 1
210000003739 neck Anatomy 0.000 claims 1
210000001672 ovary Anatomy 0.000 claims 1
210000000496 pancreas Anatomy 0.000 claims 1
239000002245 particle Substances 0.000 claims 1
210000002307 prostate Anatomy 0.000 claims 1
210000002784 stomach Anatomy 0.000 claims 1
229940063683 taxotere Drugs 0.000 claims 1
210000001550 testis Anatomy 0.000 claims 1
210000003932 urinary bladder Anatomy 0.000 claims 1
GRKFGZYYYYISDX-UHFFFAOYSA-N 6-(4-bromo-2-chloroanilino)-7-fluoro-n-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide;sulfuric acid Chemical compound OS(O)(=O)=O.OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl GRKFGZYYYYISDX-UHFFFAOYSA-N 0.000 abstract 1
150000002334 glycols Chemical class 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Physiology (AREA)
Inorganic Chemistry (AREA)
Nutrition Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

HRP20120657AT 2008-03-28 2012-08-13 Farmaceutski pripravak 271 HRP20120657T1 (hr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US4037208P	2008-03-28	2008-03-28
PCT/GB2009/050293 WO2009118562A1 (en)	2008-03-28	2009-03-26	Pharmaceutical composition 271

Publications (1)

Publication Number	Publication Date
HRP20120657T1 true HRP20120657T1 (hr)	2012-09-30

Family

ID=40792932

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HRP20120657AT HRP20120657T1 (hr)	2008-03-28	2012-08-13	Farmaceutski pripravak 271

Country Status (31)

Country	Link
US (10)	US20090246274A1 (pt)
EP (1)	EP2271321B1 (pt)
JP (2)	JP5547710B2 (pt)
KR (1)	KR101650958B1 (pt)
CN (1)	CN102046156B (pt)
AR (2)	AR071100A1 (pt)
AU (1)	AU2009229204B2 (pt)
BR (1)	BRPI0909267B8 (pt)
CA (1)	CA2718653C (pt)
CL (1)	CL2009000765A1 (pt)
CO (1)	CO6311068A2 (pt)
CY (1)	CY1113279T1 (pt)
DK (1)	DK2271321T3 (pt)
EC (1)	ECSP10010578A (pt)
ES (1)	ES2387942T3 (pt)
HK (2)	HK1149476A1 (pt)
HR (1)	HRP20120657T1 (pt)
IL (1)	IL208206A0 (pt)
MX (1)	MX2010010671A (pt)
MY (1)	MY157492A (pt)
NZ (1)	NZ588849A (pt)
PE (1)	PE20091755A1 (pt)
PL (1)	PL2271321T3 (pt)
PT (1)	PT2271321E (pt)
RS (1)	RS52409B (pt)
SA (1)	SA109300195B1 (pt)
TW (1)	TWI433840B (pt)
UA (1)	UA101654C2 (pt)
UY (1)	UY31737A (pt)
WO (1)	WO2009118562A1 (pt)
ZA (1)	ZA201006766B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI405756B (zh)	2005-12-21	2013-08-21	Array Biopharma Inc	新穎硫酸氫鹽
SA109300195B1 (ar)	2008-03-28	2013-04-20	Astrazeneca Ab	تركيبة صيدلانية جديدة مضادة للسرطان
NZ706635A (en)	2012-10-02	2018-08-31	Gilead Sciences Inc	Inhibitors of histone demethylases
EA030451B1 (ru)	2013-02-27	2018-08-31	Эпитерапьютикс Апс	Ингибиторы гистондеметилаз
TW201625535A (en)	2014-03-31	2016-07-16	Epitherapeutics Aps	Inhibitors of histone demethylases
CA2957947A1 (en)	2014-08-27	2016-03-03	Gilead Sciences, Inc.	Compounds and methods for inhibiting histone demethylases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6022852A (en)	1993-10-22	2000-02-08	Hexal Ag	Pharmaceutical composition containing cyclosporin A
WO1995027492A1 (en)	1994-04-07	1995-10-19	Smithkline Beecham P.L.C.	Halofantrine free base for the treatment of malaria and compositions
JPH11505257A (ja)	1995-05-19	1999-05-18	アボツト・ラボラトリーズ	親油性薬物の自己乳化性製剤
FR2736550B1 (fr)	1995-07-14	1998-07-24	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
MY126358A (en) *	1996-03-22	2006-09-29	Glaxo Group Ltd	Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
US5891469A (en)	1997-04-02	1999-04-06	Pharmos Corporation	Solid Coprecipitates for enhanced bioavailability of lipophilic substances
TR199901686T2 (xx)	1997-01-30	1999-09-21	Norvartis Ag	Esasen ya�s�z farmakolojik kompozisyonlar� i�eren sert jelatin kaps�ller.
US5891845A (en) *	1997-11-21	1999-04-06	Fuisz Technologies Ltd.	Drug delivery systems utilizing liquid crystal structures
US7374779B2 (en) *	1999-02-26	2008-05-20	Lipocine, Inc.	Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030104048A1 (en)	1999-02-26	2003-06-05	Lipocine, Inc.	Pharmaceutical dosage forms for highly hydrophilic materials
US6372251B2 (en)	1999-06-11	2002-04-16	Abbott Laboratories	Formulations comprising lipid-regulating agents
US20030236236A1 (en)	1999-06-30	2003-12-25	Feng-Jing Chen	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
WO2004026235A2 (en)	2002-09-20	2004-04-01	Transform Pharmaceuticals, Inc.	Pharmaceutical compositions with improved dissolution
DE60330227D1 (de)	2002-03-13	2010-01-07	Array Biopharma Inc	N3-alkylierte benzimidazol-derivate als mek-hemmer
IL165383A0 (en) *	2002-06-21	2006-01-15	Transform Pharmaceuticals Inc	Pharmaceutical compositions with improved dissolution
US20040127551A1 (en)	2002-12-27	2004-07-01	Kai Zhang	Taxane-based compositions and methods of use
US20070190129A1 (en) *	2003-09-02	2007-08-16	Pfizer Inc.	Sustained release dosage forms of ziprasidone
US20050096365A1 (en)	2003-11-03	2005-05-05	David Fikstad	Pharmaceutical compositions with synchronized solubilizer release
US20060003002A1 (en)	2003-11-03	2006-01-05	Lipocine, Inc.	Pharmaceutical compositions with synchronized solubilizer release
AR046773A1 (es)	2003-12-23	2005-12-21	Novartis Ag	Formulaciones farmaceuticas de bisfosfonatos
BRPI0418427A (pt)	2004-01-30	2007-06-12	Pfizer Italia Srl	formulações farmacêuticas de matriz semi-sólida
KR20050104152A (ko) *	2004-04-28	2005-11-02	최승호	경구용 약물의 흡수를 증진하는 약제학적 조성물
WO2006138431A2 (en)	2005-06-16	2006-12-28	Eastman Chemical Company	Methods and pharmaceutical formulations for increasing bioavailability
TWI405756B (zh) *	2005-12-21	2013-08-21	Array Biopharma Inc	新穎硫酸氫鹽
US9561178B2 (en)	2006-07-25	2017-02-07	Allergan, Inc.	Cyclosporin compositions
CN103190631B (zh)	2008-03-20	2016-01-20	维尔恩公司	非水性预乳液组合物及制备包含植物甾醇的饮料的方法
SA109300195B1 (ar)	2008-03-28	2013-04-20	Astrazeneca Ab	تركيبة صيدلانية جديدة مضادة للسرطان

2009
- 2009-03-25 SA SA109300195A patent/SA109300195B1/ar unknown
- 2009-03-26 UY UY0001031737A patent/UY31737A/es not_active Application Discontinuation
- 2009-03-26 ES ES09726304T patent/ES2387942T3/es active Active
- 2009-03-26 TW TW098109981A patent/TWI433840B/zh active
- 2009-03-26 CN CN200980120227.7A patent/CN102046156B/zh active Active
- 2009-03-26 RS RS20120357A patent/RS52409B/en unknown
- 2009-03-26 NZ NZ588849A patent/NZ588849A/en unknown
- 2009-03-26 CA CA2718653A patent/CA2718653C/en active Active
- 2009-03-26 US US12/411,865 patent/US20090246274A1/en not_active Abandoned
- 2009-03-26 KR KR1020107023140A patent/KR101650958B1/ko active Protection Beyond IP Right Term
- 2009-03-26 PT PT09726304T patent/PT2271321E/pt unknown
- 2009-03-26 BR BRPI0909267A patent/BRPI0909267B8/pt active IP Right Grant
- 2009-03-26 MX MX2010010671A patent/MX2010010671A/es active IP Right Grant
- 2009-03-26 PL PL09726304T patent/PL2271321T3/pl unknown
- 2009-03-26 DK DK09726304.0T patent/DK2271321T3/da active
- 2009-03-26 WO PCT/GB2009/050293 patent/WO2009118562A1/en active Application Filing
- 2009-03-26 MY MYPI2010004504A patent/MY157492A/en unknown
- 2009-03-26 AU AU2009229204A patent/AU2009229204B2/en active Active
- 2009-03-26 EP EP09726304A patent/EP2271321B1/en active Active
- 2009-03-26 UA UAA201012519A patent/UA101654C2/uk unknown
- 2009-03-26 JP JP2011501300A patent/JP5547710B2/ja active Active
- 2009-03-27 AR ARP090101107A patent/AR071100A1/es not_active Application Discontinuation
- 2009-03-27 CL CL2009000765A patent/CL2009000765A1/es unknown
- 2009-03-27 PE PE2009000461A patent/PE20091755A1/es not_active Application Discontinuation
2010
- 2010-09-16 IL IL208206A patent/IL208206A0/en active IP Right Grant
- 2010-09-21 ZA ZA2010/06766A patent/ZA201006766B/en unknown
- 2010-10-28 CO CO10134209A patent/CO6311068A2/es active IP Right Grant
- 2010-10-28 EC EC2010010578A patent/ECSP10010578A/es unknown
2011
- 2011-04-06 HK HK11103478.2A patent/HK1149476A1/xx unknown
- 2011-10-18 HK HK11111114.5A patent/HK1156844A1/xx unknown
- 2011-11-10 US US13/293,368 patent/US20120114750A1/en not_active Abandoned
2012
- 2012-08-13 HR HRP20120657AT patent/HRP20120657T1/hr unknown
- 2012-08-13 CY CY20121100732T patent/CY1113279T1/el unknown
2013
- 2013-01-23 US US13/747,853 patent/US20130195971A1/en not_active Abandoned
2014
- 2014-02-17 JP JP2014027398A patent/JP2014114320A/ja active Pending
2015
- 2015-10-15 US US14/884,343 patent/US20160030574A1/en not_active Abandoned
2016
- 2016-11-10 US US15/348,053 patent/US20170056375A1/en not_active Abandoned
2018
- 2018-06-29 US US16/023,102 patent/US20190030004A1/en not_active Abandoned
2019
- 2019-08-23 AR ARP190102398A patent/AR116001A2/es not_active Application Discontinuation
- 2019-10-09 US US16/597,237 patent/US20200179344A1/en not_active Abandoned
2021
- 2021-05-06 US US17/313,312 patent/US11813246B2/en active Active
2023
- 2023-10-10 US US18/484,334 patent/US20240041834A1/en active Pending
- 2023-10-10 US US18/484,337 patent/US20240041835A1/en active Pending

Also Published As

Publication number	Publication date
US20190030004A1 (en)	2019-01-31
IL208206A0 (en)	2010-12-30
EP2271321B1 (en)	2012-06-13
US20240041834A1 (en)	2024-02-08
ECSP10010578A (es)	2010-11-30
AU2009229204B2 (en)	2012-05-24
KR101650958B1 (ko)	2016-08-24
CO6311068A2 (es)	2011-08-22
ZA201006766B (en)	2011-05-25
JP2011515455A (ja)	2011-05-19
US20130195971A1 (en)	2013-08-01
KR20110005246A (ko)	2011-01-17
BRPI0909267B1 (pt)	2020-07-07
US11813246B2 (en)	2023-11-14
UY31737A (es)	2009-11-10
RS52409B (en)	2013-02-28
CA2718653C (en)	2016-02-09
BRPI0909267B8 (pt)	2021-05-25
US20240041835A1 (en)	2024-02-08
US20220087982A1 (en)	2022-03-24
US20200179344A1 (en)	2020-06-11
EP2271321A1 (en)	2011-01-12
US20090246274A1 (en)	2009-10-01
CN102046156A (zh)	2011-05-04
US20120114750A1 (en)	2012-05-10
AR071100A1 (es)	2010-05-26
HK1149476A1 (en)	2011-10-07
WO2009118562A1 (en)	2009-10-01
HK1156844A1 (en)	2012-06-22
DK2271321T3 (da)	2012-08-27
CN102046156B (zh)	2014-12-17
PE20091755A1 (es)	2009-12-13
JP2014114320A (ja)	2014-06-26
CY1113279T1 (el)	2016-04-13
BRPI0909267A2 (pt)	2017-05-30
JP5547710B2 (ja)	2014-07-16
AU2009229204A1 (en)	2009-10-01
TW200946511A (en)	2009-11-16
UA101654C2 (uk)	2013-04-25
SA109300195B1 (ar)	2013-04-20
CA2718653A1 (en)	2009-10-01
MY157492A (en)	2016-06-15
PT2271321E (pt)	2012-08-16
US20170056375A1 (en)	2017-03-02
AR116001A2 (es)	2021-03-25
RU2491920C2 (ru)	2013-09-10
ES2387942T3 (es)	2012-10-04
NZ588849A (en)	2012-06-29
MX2010010671A (es)	2011-06-20
RU2010143906A (ru)	2012-05-10
US20160030574A1 (en)	2016-02-04
CL2009000765A1 (es)	2011-02-11
TWI433840B (zh)	2014-04-11
PL2271321T3 (pl)	2013-03-29

Publication	Publication Date	Title
HRP20120657T1 (hr)	2012-09-30	Farmaceutski pripravak 271
CN101658468B (zh)	2013-03-06	辅酶q纳米结构脂质载体及其制备方法
HRP20170411T1 (hr)	2017-06-16	Amido spirocilični amidni i sulfonamidni derivati
Thakkar et al.	2014	Application of Box-Behnken design for optimization of formulation parameters for nanostructured lipid carriers of candesartan cilexetil
PH12014502271A1 (en)	2014-12-10	Composite formulation comprising multi-unit spheroidal tablet (must) encapsulated in hard capsule and method for preparing same
PH12015502134A1 (en)	2016-01-25	Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration
HRP20201048T1 (hr)	2020-10-16	Farmaceutska formulacija koja sadrži inozitol
JP2012236834A5 (pt)	2013-01-24
JP2014511383A5 (pt)	2015-04-16
RU2014129508A (ru)	2016-02-10	Новая комбинация
ES2983643T3 (es)	2024-10-24	Terapia oral con tridecanoato de testosterona
ITMI20072051A1 (it)	2009-04-24	Composizione a base di pellet di acido lipoico
CN103830201A (zh)	2014-06-04	一种度他雄胺液体软胶囊
Geronimo et al.	2021	Development of S 75: R 25 bupivacaine‐loaded lipid nanoparticles functionalized with essential oils for treating melanoma
ES2761868T3 (es)	2020-05-21	Cápsula blanda de 2,2,6,6-tetraisopropil-4,4-2-bifenol y método para la preparación de la misma
Parveen et al.	2022	RETRACTED ARTICLE: Investigation of Eutectic Mixtures of Fatty Acids as a Novel Construct for Temperature-Responsive Drug Delivery
Li et al.	2023	Nanoparticle-based combination therapy enhances fulvestrant efficacy and overcomes tumor resistance in ER-positive breast cancer
PH12014502609B1 (en)	2015-01-21	Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
CN104473910A (zh)	2015-04-01	一种普瑞巴林缓释微丸及其制备方法
CN102886047A (zh)	2013-01-23	黄芩素组合物及其制备方法
CN105581935B (zh)	2018-01-12	紫檀芪亚微米脂质粒及其制备方法
ITMI20010220A1 (it)	2002-08-05	Formulazioni multiparticolate per somministrazione orale di sali di litio idonee per una somministrazione al giorno
CN104906067B (zh)	2017-11-10	一种稳定的叶酸包合物的亚铁组合物及其制备方法与制剂
CN102283954A (zh)	2011-12-21	一种猪苓汤整合型新剂型制备技术及其生产方法
CN103271892B (zh)	2016-04-27	一种金雀异黄素阳离子纳米脂质载体及其制备方法